{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:00:19Z","timestamp":1791230419533,"version":"4.1.0"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,15]],"date-time":"2024-09-15T00:00:00Z","timestamp":1726358400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["IJC Heart & Vasculature"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.ijcha.2024.101515","type":"journal-article","created":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T20:49:16Z","timestamp":1726778956000},"page":"101515","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Effects of calcium channel blockers in patients with heart failure with preserved and mildly reduced ejection fraction: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9577-6586","authenticated-orcid":false,"given":"Hidekatsu","family":"Fukuta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiko","family":"Goto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Kamiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijcha.2024.101515_b0005","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1161\/CIRCRESAHA.119.313572","article-title":"Heart failure with preserved ejection fraction in perspective","volume":"124","author":"Pfeffer","year":"2019","journal-title":"Circ. Res."},{"key":"10.1016\/j.ijcha.2024.101515_b0010","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1056\/NEJMoa052256","article-title":"Trends in prevalence and outcome of heart failure with preserved ejection fraction","volume":"355","author":"Owan","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcha.2024.101515_b0015","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1093\/eurheartj\/ehq426","article-title":"Heart failure with preserved ejection fraction: Pathophysiology, diagnosis, and treatment","volume":"32","author":"Borlaug","year":"2011","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcha.2024.101515_b0020","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","article-title":"2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"44","author":"McDonagh","year":"2023","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcha.2024.101515_b0025","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction","volume":"381","author":"Solomon","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcha.2024.101515_b0030","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcha.2024.101515_b0035","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcha.2024.101515_b0040","first-page":"e895","article-title":"2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.ijcha.2024.101515_b0045","doi-asserted-by":"crossref","first-page":"555","DOI":"10.4070\/kcj.2017.0009","article-title":"Korean guidelines for diagnosis and management of chronic heart failure","volume":"47","author":"Kim","year":"2017","journal-title":"Korean Circ. J."},{"key":"10.1016\/j.ijcha.2024.101515_b0050","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/ejhf.442","article-title":"Spectrum of epidemiological and clinical findings in patients with heart failure with preserved ejection fraction stratified by study design: A systematic review","volume":"18","author":"Vaduganathan","year":"2016","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.ijcha.2024.101515_b0055","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1002\/ehf2.12204","article-title":"Renin-angiotensin blockade in heart failure with preserved ejection fraction: A systematic review and meta-analysis","volume":"4","author":"Khan","year":"2017","journal-title":"ESC Heart Fail."},{"key":"10.1016\/j.ijcha.2024.101515_b0060","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1007\/s10741-017-9637-0","article-title":"Effect of renin-angiotensin system inhibitors on mortality in heart failure with preserved ejection fraction: a meta-analysis of observational cohort and randomized controlled studies","volume":"22","author":"Fukuta","year":"2017","journal-title":"Heart Fail. Rev."},{"key":"10.1016\/j.ijcha.2024.101515_b0065","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1007\/s10741-020-09969-1","article-title":"Effect of renin-angiotensin system inhibition on cardiac structure and function and exercise capacity in heart failure with preserved ejection fraction: A meta-analysis of randomized controlled trials","volume":"26","author":"Fukuta","year":"2021","journal-title":"Heart Fail. Rev."},{"key":"10.1016\/j.ijcha.2024.101515_b0070","article-title":"Effects of beta-blockers on heart failure with preserved ejection fraction: A meta-analysis","volume":"9","author":"Liu","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ijcha.2024.101515_b0075","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ijcard.2016.11.239","article-title":"The effect of beta-blockers on mortality in heart failure with preserved ejection fraction: A meta-analysis of observational cohort and randomized controlled studies","volume":"228","author":"Fukuta","year":"2017","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ijcha.2024.101515_b0080","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s10741-020-10013-5","article-title":"Effect of beta-blockers on heart failure severity in patients with heart failure with preserved ejection fraction: A meta-analysis of randomized controlled trials","volume":"26","author":"Fukuta","year":"2021","journal-title":"Heart Fail. Rev."},{"key":"10.1016\/j.ijcha.2024.101515_b0085","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/0002-9149(90)90937-V","article-title":"Usefulness of verapamil for congestive heart failure associated with abnormal left ventricular diastolic filling and normal left ventricular systolic performance","volume":"66","author":"Setaro","year":"1990","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ijcha.2024.101515_b0090","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/j.1742-1241.2002.tb11193.x","article-title":"Effect of verapamil in elderly patients with left ventricular diastolic dysfunction as a cause of congestive heart failure","volume":"56","author":"Hung","year":"2002","journal-title":"Int. J. Clin. Pract."},{"key":"10.1016\/j.ijcha.2024.101515_b0095","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1161\/CIRCULATIONAHA.104.519876","article-title":"Statin therapy may be associated with lower mortality in patients with diastolic heart failure: A preliminary report","volume":"112","author":"Fukuta","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.ijcha.2024.101515_b0100","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.ijcard.2013.12.008","article-title":"Prognostic factors of heart failure with preserved ejection fraction: A 12-year prospective cohort follow-up study","volume":"171","author":"Wu","year":"2014","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ijcha.2024.101515_b0105","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1161\/CIRCHEARTFAILURE.114.001301","article-title":"Calcium channel blockers and outcomes in older patients with heart failure and preserved ejection fraction","volume":"7","author":"Patel","year":"2014","journal-title":"Circ. Heart Fail."},{"key":"10.1016\/j.ijcha.2024.101515_b0110","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1093\/eurjpc\/zwac004","article-title":"Associations between calcium channel blocker therapy and mortality in heart failure with preserved ejection fraction","volume":"29","author":"Wang","year":"2022","journal-title":"Eur. J. Prev. Cardiol."},{"key":"10.1016\/j.ijcha.2024.101515_b0115","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1002\/ejhf.3044","article-title":"Calcium channel blocker use and outcomes in patients with heart failure and mildly reduced and preserved ejection fraction","volume":"25","author":"Matsumoto","year":"2023","journal-title":"Eur. J. Heart Fail."},{"issue":"264\u2013269","key":"10.1016\/j.ijcha.2024.101515_b0120","doi-asserted-by":"crossref","first-page":"W264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"151","author":"Moher","year":"2009","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ijcha.2024.101515_b0125","doi-asserted-by":"crossref","unstructured":"Fukuta H, Goto T, Kamiya T. Effects of calcium channel blockers in patients with heart failure with preserved ejection fraction: a protocol for systematic review and meta-analysis. PLoS One. 2024;19:e0307258.","DOI":"10.1371\/journal.pone.0307258"},{"key":"10.1016\/j.ijcha.2024.101515_b0130","doi-asserted-by":"crossref","unstructured":"American Thoracic S, American College of Chest P. ATS\/ACCP Statement on cardiopulmonary exercise testing. Am J Respir Crit Care Med 2003; 167:211-277.","DOI":"10.1164\/rccm.167.2.211"},{"key":"10.1016\/j.ijcha.2024.101515_b0135","doi-asserted-by":"crossref","unstructured":"Laboratories ATSCoPSfCPF. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002; 166:111-117.","DOI":"10.1164\/ajrccm.166.1.at1102"},{"key":"10.1016\/j.ijcha.2024.101515_b0140","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/S0002-9149(77)80131-8","article-title":"New practical treadmill protocol for clinical use","volume":"39","author":"Wolthuis","year":"1977","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ijcha.2024.101515_b0145","doi-asserted-by":"crossref","unstructured":"Rector TS, Cohn JN. Assessment of patient outcome with the Minnesota Living with Heart Failure questionnaire: reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendan. Pimobendan Multicenter Research Group. Am Heart J 1992; 124:1017-1025.","DOI":"10.1016\/0002-8703(92)90986-6"},{"key":"10.1016\/j.ijcha.2024.101515_b0150","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/S0735-1097(00)00531-3","article-title":"Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: A new health status measure for heart failure","volume":"35","author":"Green","year":"2000","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcha.2024.101515_b0155","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJM198203253061202","article-title":"Heart failure in outpatients: A randomized trial of digoxin versus placebo","volume":"306","author":"Lee","year":"1982","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcha.2024.101515_b0160","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.ijcha.2024.101515_b0165","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1046\/j.1445-2197.2003.02748.x","article-title":"Methodological index for non-randomized studies (minors): Development and validation of a new instrument","volume":"73","author":"Slim","year":"2003","journal-title":"ANZ J. Surg."},{"key":"10.1016\/j.ijcha.2024.101515_b0170","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1002\/clc.24058","article-title":"Association between the beta-blockers, calcium channel blockers, all-cause mortality and length of hospitalization in patients with heart failure with preserved ejection fraction: A meta-analysis of randomized controlled trials","volume":"46","author":"Wu","year":"2023","journal-title":"Clin. Cardiol."},{"issue":"Suppl 1","key":"10.1016\/j.ijcha.2024.101515_b0175","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2165\/00129784-200707001-00003","article-title":"Calcium channel blockers: Differences between subclasses","volume":"7","author":"Frishman","year":"2007","journal-title":"Am. J. Cardiovasc. Drugs"},{"key":"10.1016\/j.ijcha.2024.101515_b0180","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.jjcc.2009.11.005","article-title":"Effects of treatment with once-daily nifedipine CR and twice-daily benidipine on prevention of symptomatic attacks in patients with coronary spastic angina pectoris-Adalat Trial vs Coniel in Tokyo against Coronary Spastic Angina (ATTACK CSA)","volume":"55","author":"Oikawa","year":"2010","journal-title":"J. Cardiol."},{"key":"10.1016\/j.ijcha.2024.101515_b0185","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/0735-1097(91)90832-T","article-title":"Exercise intolerance in patients with heart failure and preserved left ventricular systolic function: Failure of the Frank-Starling mechanism","volume":"17","author":"Kitzman","year":"1991","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcha.2024.101515_b0190","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jjcc.2023.06.014","article-title":"Characterization and prognostic importance of chronotropic incompetence in heart failure with preserved ejection fraction","volume":"83","author":"Yuasa","year":"2024","journal-title":"J. Cardiol."},{"key":"10.1016\/j.ijcha.2024.101515_b0195","doi-asserted-by":"crossref","unstructured":"Llacer P, Nunez J, Bayes-Genis A et al. Digoxin and prognosis of heart failure in older patients with preserved ejection fraction: Importance of heart rate. Results from an observational and multicenter study. Eur J Intern Med 2019; 60:18-23.","DOI":"10.1016\/j.ejim.2018.10.010"},{"key":"10.1016\/j.ijcha.2024.101515_b0200","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.jacc.2007.04.064","article-title":"Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry","volume":"50","author":"Fonarow","year":"2007","journal-title":"J. Am. Coll. Cardiol."}],"container-title":["IJC Heart & Vasculature"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352906724001817?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352906724001817?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T05:01:49Z","timestamp":1751259709000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352906724001817"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":40,"alternative-id":["S2352906724001817"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcha.2024.101515","relation":{},"ISSN":["2352-9067"],"issn-type":[{"value":"2352-9067","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of calcium channel blockers in patients with heart failure with preserved and mildly reduced ejection fraction: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"IJC Heart & Vasculature","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcha.2024.101515","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"101515"}}